SK Reports Positive Results From Phase II Study Of 21-Valent Pneumococcal Conjugate Vaccine
30/6 04:57
(RTTNews) - SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, 'GBP410' also known as SP0202, evaluating its safety and immunogenicity....